Use of tazarotene foam for the treatment of acne vulgaris

Abstract

Stamatis Gregoriou, Eleftheria Kritsotaki, Alexandros Katoulis, Dimitris RigopoulosSecond Department of Dermatology and Venereology, Attikon Hospital, University of Athens Medical School, Athens, GreeceAbstract: Acne vulgaris is a common inflammatory chronic disease of the pilosebaceous unit. It often requires long-term treatment, resulting in increased demand for topical medications that are popular with patients in order to achieve long-term compliance. Tazarotene foam 1% is a novel formulation of tazarotene. We review efficacy and tolerability studies of the new formulation, and suggest a possible place for the product in the management of acne vulgaris.Keywords: retinoids, efficacy, safety, tolerability